Search results below include Worst Pills, Best Pills Newsletter Articles where your
selected drug is a primary subject of discussion.
May 2023
Patients taking the antifungal drug voriconazole (VFEND), which is marketed in both oral and injectable forms, should be aware that it has clinically important interactions with many other prescription medications.
February 2023
Patients taking the frequently prescribed antidepressant nortriptyline (PAMELOR) should be aware that it has clinically important and potentially dangerous interactions with many other prescription and over-the-counter medications.
January 2023
Patients taking the drug sotalol (BETAPACE, BETAPACE AF, SORINE, SOTYLIZE) should be aware that it has clinically important and potentially dangerous interactions with many other prescription medications.
August 2014
Atrial fibrillation is one of the most common heart rhythm disorders, afflicting more than 2.7 million Americans. Learn about the most recent guidelines for treating this disorder, issued by the American College of Cardiology and the American Heart Association, and about Public Citizen’s Health Research Group’s assessment of those guidelines.
May 2009
Patients taking a non-selective beta blocker should make sure the provider is aware of this before they receive an injection of epinephrine, as your physician or other health care provider may not be aware that a systemic dose of epinephrine may produce a dangerous spike in blood pressure. The article lists the selective beta blockers that do not cause this problem because they do not interact with epinephrine.
December 2008
This article lists 68 drugs that can cause high blood potassium (hyperkalemia) that can result in nausea, fatigue, muscle weakness or tingling sensations, as well as heart abnormalities (showing up as an abnormal electrocardiogram). In some cases it can be fatal.
If you are taking any of these drugs, be especially careful if you have diabetes or kidney disease. If so, you are at increased risk, and your doctor will have to weigh the risk of giving you these drugs. Also, the older you are, the more likely you are to develop hyperkalemia. Also, make sure you are receiving appropriate laboratory monitoring.
March 2007
Although the FDA medical officer in charge of reviewing ranolazine recommended that ranolazine's professional product labeling display a black box warning about potential disruption in the heart's electrical cycle, the drug does not have a black box warning.